Interpreting immunoglobulin A evidence for the mucosal origins of rheumatoid arthritis autoimmunity
Abstract
Immunoglobulin A (IgA) links barrier immunity, preclinical autoimmunity, and inflammatory effector pathways in rheumatoid arthritis (RA), but these associations support different biological and clinical claims. This critical narrative review synthesizes selected human, structural, cellular, and animal studies through six dimensions: molecular identity, compartmental enrichment, local synthesis, clonal continuity, temporal order, and perturbation. Evidence coverage is distinguished from study credibility. Three judgments organize the synthesis. First, secretory component (SC)-associated anti-citrullinated protein antibody (ACPA) signals require isotype resolution: early-RA depletion experiments implicate IgM, and SC association does not by itself locate initial activation. Second, IgA1-associated progression and stronger IgA2-mediated macrophage activation suggest that predictive and effector features may differ, but comparisons across designs do not establish subclass-specific clinical roles. Third, absence of detectable autoantibodies in the tested intestinal secretions constrains luminal output in the sampled RA populations; disease stage, treatment, and antibody-specific analytical sensitivity limit extrapolation to disease initiation. Antibody assembly and longitudinal clonal relationships provide complementary information without automatically establishing anatomical origin. Clinically, SC-ACPA may enrich risk among symptomatic IgG ACPA-positive individuals, including an RF-negative subgroup. Additional diagnostic or prognostic information from IgA-RF and IgA-ACPA is assay- and decision-dependent, and current evidence does not establish IgA-guided treatment selection. A clinical schematic separates target populations, observed associations, and proposed actions requiring validation. The framework connects each interpretation to its supporting observation, limitations, and next discriminating study.
Related
- Joint–brain communication in rheumatoid arthritis: glial mechanisms, pain phenotypes, and translational evidence
- IL-23 licenses the transition from preclinical autoimmunity to inflammatory arthritis through IL-17A-dependent mechanisms
- Histone lactylation in fibroblast-like synoviocytes drives CXCL1-mediated immune cell recruitment in rheumatoid arthritis
- Serum Calprotectin as predictor of Rheumatoid Arthritis disease severity and Mortality
- Identification of a shared PAX5-mediated B-cell regulatory axis in inflammatory bowel disease and rheumatoid arthritis
BibTeX
@article{ma2026interpreting,
title = {{Interpreting immunoglobulin A evidence for the mucosal origins of rheumatoid arthritis autoimmunity}},
author = {Jilong Ma and Yong Wei and Wengxia Qi and Yuanyuan Zhang and Hailong Liu and Jiexiang Tian},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.2003986},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.2003986},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Interpreting immunoglobulin A evidence for the mucosal origins of rheumatoid arthritis autoimmunity
AU - Jilong Ma
AU - Yong Wei
AU - Wengxia Qi
AU - Yuanyuan Zhang
AU - Hailong Liu
AU - Jiexiang Tian
PY - 2026
DA - 2026/11/06
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.2003986
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.2003986
AB - Immunoglobulin A (IgA) links barrier immunity, preclinical autoimmunity, and inflammatory effector pathways in rheumatoid arthritis (RA), but these associations support different biological and clinical claims. This critical narrative review synthesizes selected human, structural, cellular, and animal studies through six dimensions: molecular identity, compartmental enrichment, local synthesis, clonal continuity, temporal order, and perturbation. Evidence coverage is distinguished from study credibility. Three judgments organize the synthesis. First, secretory component (SC)-associated anti-citrullinated protein antibody (ACPA) signals require isotype resolution: early-RA depletion experiments implicate IgM, and SC association does not by itself locate initial activation. Second, IgA1-associated progression and stronger IgA2-mediated macrophage activation suggest that predictive and effector features may differ, but comparisons across designs do not establish subclass-specific clinical roles. Third, absence of detectable autoantibodies in the tested intestinal secretions constrains luminal output in the sampled RA populations; disease stage, treatment, and antibody-specific analytical sensitivity limit extrapolation to disease initiation. Antibody assembly and longitudinal clonal relationships provide complementary information without automatically establishing anatomical origin. Clinically, SC-ACPA may enrich risk among symptomatic IgG ACPA-positive individuals, including an RF-negative subgroup. Additional diagnostic or prognostic information from IgA-RF and IgA-ACPA is assay- and decision-dependent, and current evidence does not establish IgA-guided treatment selection. A clinical schematic separates target populations, observed associations, and proposed actions requiring validation. The framework connects each interpretation to its supporting observation, limitations, and next discriminating study.
SN - 1664-3224
ER -